New Board Member

Thursday, October 20, 2022

PHRN welcomes to our Board a new member, Liddy McCall.  Liddy McCall brings diverse experience as an investor, inventor and executive management achieving multiple successful commercial outcomes for early stage Australian biotechnology research and IT projects. She co-founded the Yuuwa Capital early-stage venture fund supporting a portfolio of early stage opportunities into clinical stage biotechnology and global IT companies. She was a director of Agworld Pty Ltd which was acquired for over A$100m by Canadian company, Semios in 2021 creating one of the largest independent global digital solutions providers for the data-driven farm management platform using a complex data and permissions model supporting industry (e.g. growers, agronomists, retailers, service providers including financial, operational etc). She co-founded iCeutica group (US & Australian entities) leveraging UWA research achieving an exit >10x for early-stage investors and now with 3 FDA approved drugs. She was a co-founded and is a co-inventor on granted patents behind the drug therapeutic being developed by ASX-listed, Dimerix Limited’ multiple phase 3 clinical trials in kidney and respiratory diseases.

Prior to Liddy’s involvement in technology commercialisation, she was an Associate Director in Corporate Advisory at Macquarie Bank focused on mergers and acquisitions. Liddy has qualifications in law, finance and management. Liddy is a board director of a number of ASX listed and unlisted entities including not-for-profit. She also provides advisory support for diverse start-up companies. Liddy applies her diverse skills and experience to encourage and support Australian entrepreneurs to translate research into commercial outcomes. She looks for novel approaches to achieve that can benefit to Australian researchers to showcase their innovations and drive outcomes in the global economy.